Evaluation of the Pharmacokinetics and Safety of Inaxaplin in Participants With Mild or Moderate Hepatic Impairment

Key Inclusion Criteria: * Cohorts 1 and 3: Participants with Hepatic Impairment * Cohort 1 (mild impairment): defined as a Child-Pugh total score of 5 to 6 (Child-Pugh Class A) * Cohort 3 (moderate impairment): defined as a Child-Pugh total score of 7 to 9 (Child-Pugh Class B) * Cohorts 2 and 4: Healthy Participants * Participants will be matched during screening to participants with mild (Cohort 1) or moderate (Cohort 3) hepatic impairment according to each of the following parameters: age (± 10 years); sex; and BMI (± 15%) Key Exclusion Criteria: * Cohorts 1 and 3: Participants with Hepatic Impairment * Acute febrile illness within 14 days and/or acute illness within 5 days before first dose of study drug * Participants who smoke * Cohorts 2 and 4: Healthy Participants * Acute febrile illness within 14 days and/or acute illness within 5 days before first dose of study drug * Any condition possibly affecting drug absorption Other protocol defined Inclusion/Exclusion criteria may apply